The effect of vasopressin and related compounds at V1a and V2 receptors in animal models relevant to human disease

Basic and Clinical Pharmacology and Toxicology

Volumn 99, Issue 2, 2006, Pages 96-103

  Petersen, Mads Bjelke ^a  

^a Ferring Pharmaceuticals AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DESMOPRESSIN; F 180; KAPPA OPIATE RECEPTOR AGONIST; OPCV 51803; TERLIPRESSIN; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1A RECEPTOR STIMULATING AGENT; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN V2 RECEPTOR STIMULATING AGENT; WAY VNA 932;

BLOOD CLOTTING DISORDER; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES INSIPIDUS; DISEASE MODEL; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG USE; ESOPHAGUS VARICES BLEEDING; FLUID BALANCE; HOMEOSTASIS; HUMAN; KIDNEY; NONHUMAN; PORTAL HYPERTENSION; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; RECEPTORS, VASOPRESSIN; REPRODUCIBILITY OF RESULTS; SPECIES SPECIFICITY; VASOPRESSINS;

ANIMALIA;

EID: 33747057973     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.pto_299.x     Document Type: Conference Paper

References (102)

1. Agre, P., M. Bonhivers & M. J. Borgnia: The aquaporins, blueprints for cellular plumbing systems. J. Biol. Chem. 1998, 273, 14659-14662.
2. Albert, M., M. R. Losser, D. Hayon, V. Faivre & D. Payen: Systemic and renal macro- and microcirculatory responses to arginine vasopressin in endotoxic rabbits. Crit. Care Med. 2004, 32, 1891-1898.
3. Andres, M., A. Pena, S. Derick, D. Raufaste, J. Trojnar, K. Wisniewski, M. Trueba, C. Serradeil-le Gal & G. Guillon: Comparative pharmacology of bovine, human and rat vasopressin receptor isoforms. Eur. J Pharmacol. 2004, 501, 59-69.
4. Asfar, P., B. Hauser, Z. Ivanyi, U. Ehrmann, J. Kick, M. Albicini, J. Vogt, U. Wachter, U. B. Bruckner, P. Radermacher & H. Bracht: Low-dose terlipressin during long-term hyperdynamic porcine endotoxemia: effects on hepatosplanchnic perfusion, oxygen exchange, and metabolism. Crit. Care Med. 2005, 33, 373-380.
5. Asfar, P., M. Pierrot, N. Veal, F. Moal, F. Oberti, V. Croquet, O. Douay, Y. Gallois, J. L. Saumet, P. Alquier & P. Cales: Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Crit. Care Med. 2003, 31, 215-220.
6. Barberis, C., B. Mouillac & T. Durroux: Structural bases of vasopressin/oxytocin receptor function. J. Endocrinol. 1998, 156, 223-229.
7. Baylis, P. H.: Regulation of vasopressin secretion. Baillieres Clin. Endocrinol. Metab 1989, 3, 313-330.
8. Baylis, P. H. & T. Cheetham: Diabetes insipidus. Arch. Dis. Child 1998, 79, 84-89.
9. Baylis, P. H., C. Pippard, G. V. Gill & J. Burd: Development of a cytochemical assay for plasma vasopressin: application to studies on water loading normal man. Clin. Endocrinol. (Oxf) 1986, 24, 383-393.
10. Bernadich, C., J. C. Bandi, P. Melin & J. Bosch: Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension. Hepatology 1998, 27, 351-356.
11. Bernat, A., P. Hoffmann, A. Dumas, C. Serradeil-le Gal, D. Raufaste & J. M. Herbert: V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs. J. Pharmacol. Exp. Therap. 1997, 282, 597-602.
12. Bichet, D. G., M. Razi, M. Lonergan, M. F. Arthus, V. Papukna, C. Kortas & J. N. Barjon: Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. New Engl. J Med. 1988, 318, 881-887.
13. Birnbaumer, M.: V2R structure and diabetes insipidus. Receptors Channels 2002, 8, 51-56.
14. Birnbaumer, M., A. Seibold, S. Gilbert, M. Ishido, C. Barberis, A. Antaramian, P. Brabet & W. Rosenthal: Molecular cloning of the receptor for human antidiuretic hormone. Nature 1992, 357, 333-335.
15. Blei, A. T., R. J.Groszmann, R. Gusberg &H. O. Conn: Comparison of vasopressin and triglycyl-lysine vasopressin on splanchnic and systemic hemodynamics in dogs. Dig. Dis. Sci. 1980, 25, 688-694.
16. Bourque, C. W. & S. H. Oliet: Osmoreceptors in the central nervous system. Annu. Rev. Physiol 1997, 59, 601-619.
17. Bourque, C. W., S. H. Oliet & D. Richard: Osmoreceptors, osmoreception, and osmoregulation. Front. Neuroendocrinol. 1994, 15, 231-274.
18. Bowie, E. J., L. A. Solberg, Jr., D. N. Fass, C. M. Johnson, G. J. Knutson, M. L. Stewart & L. J. Zoecklein: Transplantation of normal bone marrow into a pig with severe von Willebrand's disease. J. Clin. Invest. 1986, 78, 26-30.
19. Brooks, D. P., P. F. Koster, F. L. Stassen, C. R. Albrightson, W. F. Huffman, M. A. Wasserman & L. B. Kinter: Flushing and haemodynamic responses to vasopressin peptides in the rhesus monkey. Brit. J. Pharmacol. 1988, 94, 759-764.
20. Butler, K. D., S. L. Dolan, M. D. Talbot & R. B. Wallis: Factor VIII and DDAVP reverse the effect of recombinant desulphatohirudin (CGP 39393) on bleeding in the rat. Blood Coagul. Fibrinolysis 1993, 4, 459-464.
21. Caggiano, T. J.: WAY-VNA-932. Treatment of central diabetes insipidus, treatment of nocturnal enuresis, treatment of nocturia vasopressin V2 agonist. Drugs of the Future 2002, 27, 248-253.
22. Callréus, T. & P. Höglund: Pharmacokinetics and antidiuretic effect of intravenous administration of desmopressin in orally overhydrated male volunteers. Pharmacology & Toxicology 1998, 83, 259-262.
23. D'Amico, G., M. Traina, G. Vizzini, F. Tine, F. Politi, L. Montalbano, A. Luca, L. Pasta, L. Pagliaro & A. Morabito: Terlipressin or vasopressin plus transdermal nitroglycerin in a treatment strategy for digestive bleeding in cirrhosis. A randomized clinical trial. Liver Study Group of V. Cervello Hospital. J. Hepatol. 1994, 20, 206-212.
24. Erwald, R. & K. L. Wiechel: Effect of vasopressin on central and splanchnic hemodynamics in awake man. Acta Chir. Scand. 1978, 144, 347-358.
25. Esmon, C. T.: Why do animal models (sometimes) fail to mimic human sepsis? Crit. Care Med. 2004, 32, S219-S222.
26. Ferguson, J. N., L. J. Young & T. R. Insel: The neuroendocrine basis of social recognition. Front Neuroendocrinol. 2002, 23, 200-224.
27. Fushimi, K., S. Uchida, Y. Hara, Y. Hirata, F. Marumo & S. Sasaki: Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 1993, 361, 549-552.
28. Guillon, G., D. Butlen, B. Cantau, T. Barth & S. Jard: Kinetic and pharmacological characterization of vasopressin membrane receptors from human kidney medulla: relation to adenylate cyclase activation. Eur. J Pharmacol. 1982, 85, 291-304.
29. Guzman, J. A., A. E. Rosado & J. A. Kruse: Vasopressin vs norepinephrine in endotoxic shock: systemic, renal, and splanchnic hemodynamic and oxygen transport effects. J. Appl. Physiol 2003, 95, 803-809.
30. Hansen, E. F., C. Strandberg, L. Hojgaard, J. Madsen, J. H. Henriksen, T. V. Schroeder, U. Becker & F. Bendtsen: Splanchnic haemodynamics after intravenous terlipressin in anaesthetised healthy pigs. J. Hepatol. 1999, 30, 503-510.
31. Hayashi, M., S. Sasaki, H. Tsuganezawa, T. Monkawa, W. Kitajima, K. Konishi, K. Fushimi, F. Marumo & T. Saruta: Expression and distribution of aquaporin of collecting duct are regulated by vasopressin V2 receptor in rat kidney. J. Clin. Invest. 1994, 94, 1778-1783.
32. Heinemann, A., C. H. Wachter, P. Fickert, M. Trauner & R. E. Stauber: Vasopressin reverses mesenteric hyperemia and vasoconstrictor hyporesponsiveness in anesthetized portal hypertensive rats. Hepatology 1998, 28, 646-654.
33. Heiniger, J., L. Kissling-Albrecht, S. Neuenschwander, R. Rosli & V. Pliska: Antihaemophilic effect of vasopressin, deamino-(D-arginine8)-vasopressin and adrenaline in sheep: proposal for an in vivo assay system. Brit. J. Pharmacol. 1988, 94, 279-281.
34. Johns, R. A.: Desmopressin is a potent vasorelaxant of aorta and pulmonary artery isolated from rabbit and rat. Anesthesiology 1990, 72, 858-864.
35. Johnson, G. S., K. H. Kraus, M. A. Turrentine & P. W. Dean: DDAVP-induced increases in coagulation factor VIII and von Willebrand factor in the plasma of conscious dogs. J. Vet. Pharmacol. Therap. 1986, 9, 370-375.
36. Johnstone, I. B. & S. Crane: The effects of desmopressin on plasma factor VIII/von Willebrand factor activity in dogs with von Willebrand's disease. Can. J. Vet. Res. 1987, 51, 189-193.
37. Kamoi, K., F. Sato, O. Arai, M. Ishibashi & T. Yamaji: Effects of plasma volume and osmolality on secretion of atrial natriuretic peptide and vasopressin in man. Acta Endocrinol. (Copenh) 1988, 118, 51-58.
38. Kaufmann, J. E., A. Oksche, C. B. Wollheim, G. Gunther, W. Rosenthal & U. M. Vischer: Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J. Clin. Invest. 2000, 106, 107-116.
39. Kaufmann, J. E. & U. M. Vischer: Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J. Thromb. Haemost. 2003, 1, 682-689.
40. Kinter, L. B. & R. Beeuwkes III: Oral antidiuretic therapy: studies in the diabetes insipidus rat. Amer. J. Physiol. 1982, 243, R491-R499.
41. Kinter, L. B., I. McConnell, B. T. Goodwin, S. Campbell, W. F. Huffman, Arthus- M-F, M. Lonergan & D. G. Bichet: Vasopressin antagonist inhibition of clotting factor release in the rhesus monkey (Macaca mulatta). J. Pharmacol. Exp. Therap. 1992, 261, 462-469.
42. Kompanowska-Jezierska, E., C. Emmeluth, L. Grove, P. Christensen, J. Sadowski & P. Bie: Mechanism of vasopressin natriuresis in the dog: role of vasopressin receptors and prostaglandins. Amer. J. Physiol. 1998, 274, R1619-R1625.
43. Kraus, K. H., M. A. Turrentine, A. E. Jergens & G. S. Johnson: Effect of desmopressin acetate on bleeding times and plasma von Willebrand factor in Doberman pinscher dogs with von Willebrand's disease. Vet. Surg. 1989, 18, 103-109.
44. Landry, D. W., H. R. Levin, E. M. Gallant, R. C. Ashton, Jr., S. Seo, D. D'Alessandro, M. C. Oz & J. A. Oliver: Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997, 95, 1122-1125.
45. Leander, J. D.: Further study of kappa opioids on increased urination. J. Pharmacol. Exp. Therap. 1983, 227, 35-41.
46. Leander, J. D., R. L. Zerbe & J. C. Hart: Diuresis and suppression of vasopressin by kappa opioids: comparison with mu and delta opioids and clonidine. J. Pharmacol. Exp. Therap. 1985, 234, 463-469.
47. Lebrec, D., R. Moreau, S. Cailmail, P. Sogni, F. Oberti & A. Hadengue: Effects of terlipressin on hemodynamics and oxygen content in conscious portal vein stenosed and cirrhotic rats receiving propranolol. J. Hepatol. 1993, 17, 102-107.
48. Leone, M., J. Albanese, A. Delmas, W. Chaabane, F. Garnier & C. Martin: Terlipressin in catecholamine-resistant septic shock patients. Shock 2004, 22, 314-319.
49. Leung, F. W., D. M. Jensen & P. H. Guth: Endoscopic demonstration that vasopressin but not propranolol produces gastric mucosal ischemia in dogs with portal hypertension. Gastrointest. Endosc. 1988, 34, 310-313.
50. Levy, B., C. Vallee, F. Lauzier, G. E. Plante, A. Mansart, J. P. Mallie & O. Lesur: Comparative effects of vasopressin, norepinephrine, and L-canavanine, a selective inhibitor of inducible nitric oxide synthase, in endotoxic shock. Amer. J. Physiol. Heart Circ. Physiol. 2004, 287, H209-H215.
51. Liard, J. F.: cAMP and extrarenal vasopressin V2 receptors in dogs. Amer. J. Physiol 1992, 263, H1888-H1891.
52. Liard, J. F.: Characterization of acute hemodynamic effects of anti-diuretic agonists in conscious dogs. J. Cardiovasc. Pharmacol. 1988, 11, 174-180.
53. Lundin, S., P. Melin & H. Vilhardt: Plasma concentrations of 1-deamino-8-D-arginine vasopressin after intragastric administration in the rat. Acta Endocrinol. (Copenh) 1985, 108, 179-183.
54. Lush, C. W. & P. R. Kvietys: Microvascular dysfunction in sepsis. Microcirculation. 2000, 7, 83-101.
55. Malay, M. B., J. L. Ashton, K. Dahl, E. B. Savage, S. A. Burchell, R. C. Ashton, Jr., R. R. Sciacca, J. A. Oliver & D. W. Landry: Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. Crit. Care Med. 2004, 32, 1327-1331.
56. Malay, M. B., R. C. Ashton, Jr., D. W. Landry & R. N. Townsend: Low-dose vasopressin in the treatment of vasodilatory septic shock. J. Trauma 1999, 47, 699-703.
57. Mannucci, P. M.: Desmopressin (DDAVP) for treatment of disorders of hemostasis. Prog. Hemost. Thromb. 1986, 8, 19-45.
58. Martikainen, T. J., J. J. Tenhunen, A. Uusaro & E. Ruokonen: The effects of vasopressin on systemic and splanchnic hemodynamics and metabolism in endotoxin shock. Anesth. Analg. 2003, 97, 1756-1763.
59. Martinez, M. C., M. Aldasoro, J. M. Vila, P. Medina & S. Lluch: Responses to vasopressin and desmopressin of human cerebral arteries. J Pharmacol. Exp. Therap. 1994a, 270, 622-627.
60. Martinez, M. C., J. M. Vila, M. Aldasoro, P. Medina, B. Flor & S. Lluch: Relaxation of human isolated mesenteric arteries by vasopressin and desmopressin. Brit. J Pharmacol. 1994b, 113, 419-424.
61. Mechaly, I., F. Laurent, K. Portet, J. Serrano & G. Cros: Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur. J. Pharmacol. 1999, 383, 287-290.
62. Medina, P., G. Segarra, J. M. Vila, P. Chuan, C. Domenech & S. Lluch: V2-receptor-mediated relaxation of human renal arteries in response to desmopressin. Amer. J. Hypertens. 1999, 12, 188-193.
63. Morales, D., J. Madigan, S. Cullinane, J. Chen, M. Heath, M. Oz, J. A. Oliver & D. W. Landry: Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Circulation 1999, 100, 226-229.
64. Morales, J., E. Moitinho, J. G. Abraldes, M. Fernandez & J. Bosch: Effects of the V1a vasopressin agonist F-180 on portal hypertension-related bleeding in portal hypertensive rats. Hepatology 2003, 38, 1378-1383.
65. Moreau, R., S. Cailmail, D. Valla & D. Lebrec: Haemodynamic responses to a combination of terlipressin and octreotide in portal hypertensive rats. Aliment. Pharmacol. Therap. 1997, 11, 993-997.
66. Morelli, A., M. Rocco, G. Conti, A. Orecchioni, G. A. De, G. Cortese, F. Coluzzi, E. Vernaglione, P. Pelaia & P. Pietropaoli: Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med. 2004, 30, 597-604.
67. Nakamura, S., T. Hirano, T. Onogawa, S. Itoh, A. Hashimoto, Y. Yamamura, K. Kondo, T. Mori & T. Kambe: Antidiuretic effects of a novel nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to dogs. J. Pharmacol. Sci. 2004, 94, 426-433.
68. Nakamura, S., T. Hirano, K. Tsujimae, M. Aoyama, K. Kondo, Y. Yamamura, T. Mori & M. Tominaga: Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats. J. Pharmacol. Exp. Therap. 2000, 295, 1005-1011.
69. Nakamura, S., T. Hirano, Y. Yamamura, S. Itoh, K. Kondo, T. Mori & T. Kambe: Effects of OPC-51803, a novel, nonpeptide vasopressin V2-receptor agonist, on micturition frequency in Brattleboro and aged rats. J. Pharmacol. Sci. 2003, 93, 484-488.
70. Nielsen, S., J. Frokiaer, D. Marples, T. H. Kwon, P. Agre & M. A. Knepper: Aquaporins in the kidney: from molecules to medicine. Physiol. Rev. 2002, 82, 205-244.
71. Ohnishi, A., M. Mihara, S. Yasuda, Y. Tomono, J. Hasegawa & T. Tanaka: Aquaretic effect of the stable dynorphin-A analog E2078 in the human. J. Pharmacol. Exp. Therap. 1994, 270, 342-347.
72. Patel, B. M., D. R. Chittock, J. A. Russell & K. R. Walley: Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002, 96, 576-582.
73. Ring, R. H.: The central vasopressinergic system: examining the opportunities for psychiatric drug development. Curr. Pharm. Des 2005, 11, 205-225.
74. Scharte, M., J. Meyer, H. Van Aken & H. G. Bone: Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep. Crit. Care Med. 2001, 29, 1756-1760.
75. Sielenkämper, A. W., J. Meyer, H. Kloppenburg, K. Eicker & H. Van Aken: The effects of sepsis on gut mucosal blood flow in rats. Eur. J. Anaesthesiol. 2001, 18, 673-678.
76. Singer, I., J. R. Oster & L. M. Fishman: The management of diabetes insipidus in adults. Arch. Intern. Med. 1997, 157, 1293-1301.
77. Slizgi, G. R. & J. H. Ludens: Studies on the nature and mechanism of the diuretic activity of the opioid analgesic ethylketocyclazocine. J. Pharmacol. Exp. Therap. 1982, 220, 585-591.
78. Slizgi, G. R., C. J. Taylor & J. H. Ludens: Effects of the highly selective kappa opioid, U-50, 488, on renal function in the anesthetized dog. J. Pharmacol. Exp. Therap. 1984, 230, 641-645.
79. Söderlund, C., I. Magnusson, S. Torngren & L. Lundell: Terlipressin (triglycyl-lysine vasopressin) controls acute bleeding oesophageal varices. A double-blind, randomized, placebo-controlled trial. Scand. J. Gastroenterol. 1990, 25, 622-630.
80. Sugimoto, T., M. Saito, S. Mochizuki, Y. Watanabe, S. Hashimoto & H. Kawashima: Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. J. Biol. Chem. 1994, 269, 27088-27092.
81. Sun, Q., G. Dimopoulos, D. N. Nguyen, Z. Tu, N. Nagy, A. D. Hoang, P. Rogiers, D. De Backer & J. L. Vincent: Low-dose vasopressin in the treatment of septic shock in sheep. Amer. J. Respir. Crit. Care Med. 2003, 168, 481-486.
82. Sweeney, J. D., E. K. Novak, M. Reddington, K. H. Takeuchi & R. T. Swank: The RIIIS/J inbred mouse strain as a model for von Willebrand disease. Blood 1990, 76, 2258-2265.
83. Tahara, A., J. Tsukada, N. Ishii, Y. Tomura, K. Wada, T. Kusayama, T. Yatsu, W. Uchida & A. Tanaka: Characterization of rodent liver and kidney AVP receptors: pharmacologic evidence for species differences. Regul. Pept. 1999, 84, 13-19.
84. Thibonnier, M., C. Auzan, Z. Madhun, P. Wilkins, L. Berti-Mattera & E. Clauser: Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J. Biol. Chem. 1994, 269, 3304-3310.
85. Thibonnier, M., L. N. Berti-Mattera, N. Dulin, D. M. Conarty & R. Mattera: Signal transduction pathways of the human V1-vascular, V2-renal, V3-pituitary vasopressin and oxytocin receptors. Prog. Brain Res. 1998, 119, 147-161.
86. Thrasher, T. N.: Baroreceptor regulation of vasopressin and renin secretion: low-pressure versus high-pressure receptors. Front Neuroendocrinol. 1994, 15, 157-196.
87. Tranquille, N. & J. J. Emeis: The simultaneous acute release of tissuetype plasminogen activator and von Willebrand factor in the perfused rat hindleg region. Thromb. Haemost. 1990, 63, 454-458.
88. Ufer, E., R. Postina, V. Gorbulev & F. Fahrenholz: An extracellular residue determines the agonist specificity of V2 vasopressin receptors. FEBS Lett. 1995, 362, 19-23.
89. Valtin, H. & H. A. Schroeder: Familial hypothalamic diabetes insipidus in rats (Brattleboro strain). Amer. J. Physiol 1964, 206, 425-430.
90. Vavra, I., A. Machova, V. Holecek, J. H. Cort, M. Zaoral & F. Sorm: Effect of a synthetic analogue of vasopressin in animals and in patients with diabetes insipidus. Lancet 1968, 1, 948-952.
91. Vavra, I., A. Machova & I. Krejci: Antidiuretic action of 1-deamino-(8-D-arginine)-vasopressin in unanesthetized rats. J. Pharmacol. Exp. Therap. 1974, 188, 241-247.
92. Vicente, V., A. Estelles, J. Laso, J. M. Moraleda, J. Rivera & J. Aznar: Repeated infusions of DDAVP induce low response of FVIII and vWF but not of plasminogen activators. Thromb. Res. 1993, 70, 117-122.
93. Vilhardt, H. & T. Barth: Factor VIII and tissue plasminogen activator in monkeys after administration of DDAVP analogues. Thromb. Res. 1992, 68, 501-504.
94. Vilhardt, H. & T. Barth: The release of factor VIII and tissue plasminogen activator can not be blocked by specific antagonists to vasopressin. J. Recept. Res. 1991, 11, 239-245.
95. Vilhardt, H., T. Barth, J. Falch & I. M. Nilsson: Plasma concentrations of factor VIII after administration of DDAVP to conscious dogs. Thromb. Res. 1987, 47, 585-591.
96. Vilhardt, H., T. Barth, P. Melin & C. J. Aurell: Antidiuretic activity and release of factor VIII by vasopressin analogues. Eur. J. Pharmacol. 1993, 232, 223-226.
97. Vilhardt, H. & P. Bie: Antidiuretic effect of perorally administered DDAVP in hydrated humans. Acta Endocrinol. (Copenh) 1984, 105, 474-476.
98. Vilhardt, H. & P. Bie: Antidiuretic response in conscious dogs following peroral administration of arginine vasopressin and its analogues. Eur. J. Pharmacol. 1983, 93, 201-204.
99. Vilhardt, H. & S. Lundin: Biological effect and plasma concentrations of DDAVP after intranasal and peroral administration to humans. Gen. Pharmacol. 1986, 17, 481-483.
100. Westphal, M., H. Freise, B. E. Kehrel, H. G. Bone, H. Van Aken & A. W. Sielenkamper: Arginine vasopressin compromises gut mucosal microcirculation in septic rats. Crit. Care Med. 2004, 32, 194-200.
101. Westphal, M., H. Stubbe, A. W. Sielenkamper, C. Ball, H. Van Aken, R. Borgulya & H. G. Bone: Effects of titrated arginine vasopressin on hemodynamic variables and oxygen transport in healthy and endotoxemic sheep. Crit. Care Med. 2003a, 31, 1502-1508.
102. Westphal, M., H. Stubbe, A. W. Sielenkamper, R. Borgulya, H. Van Aken, C. Ball & H. G. Bone: Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport. Intensive Care Med. 2003b, 29, 301-308.